| Names | |
|---|---|
| Preferred IUPAC name Cyclohexyl ([1,1′-biphenyl]-3-yl)carbamate | |
| Other names [1,1′-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider | |
PubChem CID | |
| UNII | |
CompTox Dashboard (EPA) | |
| |
| |
| Properties | |
| C19H21NO2 | |
| Molar mass | 295.382 g·mol−1 |
| Appearance | Crystalline solid |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
URB602 ([1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl ester) is a compound that has been found to inhibit hydrolysis of monoacyl glycerol compounds, such as 2-arachidonoylglycerol (2-AG) and 2-oleoylglycerol (2-OG). It was first described in 2003. [1] A study performed in 2005 found that the compound had specificity for metabolizing 2-AG over anandamide (another cannabinoid ligand) in rat brain presumably by inhibiting the enzyme monoacylglycerol lipase (MAGL), which is the primary metabolic enzyme of 2-AG. [2] However, subsequent studies have shown that URB602 lacks specificity for MAGL inhibition in vitro. [3]